{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:13:43Z","timestamp":1760044423541,"version":"3.44.0"},"reference-count":16,"publisher":"The Pediatric Pharmacy Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p>Non-stimulant medication therapy for children, adolescents, and young adults with attention-deficit\/hyperactivity disorder (ADHD) has included alpha 2-agonists (guanfacine and clonidine) as well as a norepinephrine reuptake inhibitor (atomoxetine) for multiple years. Although these may be effective options for some children, they are generally considered to be less effective than stimulant medications. In addition, there has been a suicidal ideation concern in early-late adolescence with atomoxetine, emphasizing the need for continued development of other treatment options.<\/jats:p>\n        <jats:p>Extended-release viloxazine (SPN-812) has been shown in phase 2 and phase 3 trials to be an effective, well-tolerated alternative for some children with ADHD. The mechanism of action of viloxazine is unique, modulating activity of both serotonin and norepinephrine. Treatment-related adverse events most commonly seen included somnolence, decreased appetite, and headache. Although continued evaluation to confirm the reduced symptoms of ADHD in children along with the safety profile is needed, extended-release viloxazine may offer a once-a-day pharmaceutical treatment option for patients in which stimulant medication is not effective or not a favorable option. It may also be beneficial for those children and adolescents with a comorbidity of depression.<\/jats:p>","DOI":"10.5863\/1551-6776-27.5.409","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T14:51:55Z","timestamp":1657119115000},"page":"409-414","source":"Crossref","is-referenced-by-count":4,"title":["Extended-Release Viloxazine for Children and Adolescents With Attention Deficit Hyperactivity Disorder"],"prefix":"10.5863","volume":"27","author":[{"given":"Keith","family":"Mather","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Oklahoma School of Community Medicine, Tulsa, OK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Condren","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Oklahoma School of Community Medicine, Tulsa, OK."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"2","key":"i2331-348X-27-5-409-b1","series-title":"J Clin Child Adolesc Psychol","first-page":"199","article-title":"Prevalence of parent-reported ADHD diagnosis and associated treatment among US children and adolescents, 2016","volume":"47","year":"2018","unstructured":"Danielson\n              ML,\n            \n            \n              Bitsko\n              RH,\n            \n            \n              Ghandour\n              RM,\n            \n          \n          .\n\t\t\t\t\tPrevalence of parent-reported ADHD diagnosis and associated treatment among US children and adolescents, 2016.\n\t\t\t\t\tJ Clin Child Adolesc Psychol.\n\t\t\t\t\t2018;\n\t\t\t\t\t47(\n\t\t\t\t\t2):\n\t\t\t\t\t199\u2013\n\t\t\t\t\t212."},{"issue":"4","key":"i2331-348X-27-5-409-b2","series-title":"Pediatrics","first-page":"e20192528","article-title":"Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents","volume":"144","year":"2019","unstructured":"Wolraich\n              M,\n            \n            \n              Hagan\n              J,\n            \n            \n              Allan\n              C,\n            \n          \n          .\n\t\t\t\t\tClinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents.\n\t\t\t\t\tPediatrics.\n\t\t\t\t\t2019;\n\t\t\t\t\t144(\n\t\t\t\t\t4):\n\t\t\t\t\te20192528."},{"year":"2020","unstructured":"Centers for Disease Control and Prevention.\n\t\t\t\t\t\n          Treatment of ADHD.\n\t\t\t\t\tAtlanta, GA:\n\t\t\t\t\t2020.\n\t\t\t\t\tAccessed July 23, 2021. https:\/\/www.cdc.gov\/ncbddd\/adhd\/treatment.html.","article-title":"Treatment of ADHD","key":"i2331-348X-27-5-409-b3"},{"issue":"1","key":"i2331-348X-27-5-409-b4","series-title":"J Pediatrics","first-page":"240","article-title":"A national description of treatment among US children and adolescents with ADHD","volume":"192","year":"2018","unstructured":"Danielson\n              ML,\n            \n            \n              Visser\n              SN,\n            \n            \n              Chronis-Tuscano\n              A,\n            \n            \n              DuPaul\n              GJ.\n            \n          \n          A national description of treatment among US children and adolescents with ADHD.\n\t\t\t\t\tJ Pediatrics.\n\t\t\t\t\t2018;\n\t\t\t\t\t192(\n\t\t\t\t\t1):\n\t\t\t\t\t240\u2013\n\t\t\t\t\t246."},{"issue":"4","key":"i2331-348X-27-5-409-b5","series-title":"J Am Acad Child Adolesc Psychiatry","first-page":"409","article-title":"Pharmaco-therapy of attention-deficit hyperactivity disorder across the life cycle","volume":"35","year":"1996","unstructured":"Spencer\n              T,\n            \n            \n              Biederman\n              J,\n            \n            \n              Wilens\n              T,\n            \n          \n          .\n\t\t\t\t\tPharmaco-therapy of attention-deficit hyperactivity disorder across the life cycle.\n\t\t\t\t\tJ Am Acad Child Adolesc Psychiatry.\n\t\t\t\t\t1996;\n\t\t\t\t\t35(\n\t\t\t\t\t4):\n\t\t\t\t\t409\u2013\n\t\t\t\t\t432."},{"issue":"6","key":"i2331-348X-27-5-409-b6","series-title":"J Clin Psychiatry","first-page":"754","article-title":"A comparison of the efficacy of medications for adult attention-deficit\/hyperactivity disorder using meta-analysis of effect sizes","volume":"71","year":"2010","unstructured":"Faraone\n              SV,\n            \n            \n              Glatt\n              SJ.\n            \n          \n          A comparison of the efficacy of medications for adult attention-deficit\/hyperactivity disorder using meta-analysis of effect sizes.\n\t\t\t\t\tJ Clin Psychiatry.\n\t\t\t\t\t2010;\n\t\t\t\t\t71(\n\t\t\t\t\t6):\n\t\t\t\t\t754\u2013\n\t\t\t\t\t763."},{"year":"2017","unstructured":"Strattera (atomoxetine) [prescribing information].\n\t\t\t\t\tIndianapolis, IN:\n\t\t\t\t\tEli Lilly and Company, LLC;\n\t\t\t\t\t2017.","article-title":"Strattera (atomoxetine) [prescribing information]","key":"i2331-348X-27-5-409-b7"},{"year":"2016","unstructured":"Intuniv (guanfacine extended-release) [prescribing information].\n\t\t\t\t\tLexington, MA:\n\t\t\t\t\tShire US, Inc;\n\t\t\t\t\t2016.","article-title":"Intuniv (guanfacine extended-release) [prescribing information]","key":"i2331-348X-27-5-409-b8"},{"key":"i2331-348X-27-5-409-b9","series-title":"J Experimental Pharmacol","first-page":"285","article-title":"New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties","volume":"12","year":"2020","unstructured":"Yu\n              C,\n            \n            \n              Garcia-Olivares\n              J,\n            \n            \n              Candler\n              S,\n            \n          \n          .\n\t\t\t\t\tNew insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties.\n\t\t\t\t\tJ Experimental Pharmacol.\n\t\t\t\t\t2020;\n\t\t\t\t\t12:\n\t\t\t\t\t285\u2013\n\t\t\t\t\t300."},{"year":"2021","unstructured":"Qelbree (viloxazine extended-release) [prescribing information].\n\t\t\t\t\tRockville, MD:\n\t\t\t\t\tSupernus Pharmaceuticals, Inc;\n\t\t\t\t\t2021.","article-title":"Qelbree (viloxazine extended-release) [prescribing information]","key":"i2331-348X-27-5-409-b10"},{"key":"i2331-348X-27-5-409-b11","series-title":"Psychoparmacol Bul","first-page":"43","article-title":"A phase 3 placebo-controlled trial of once daily 400 mg and 600 mg SPN-812 (viloxazine extended release) in adolescents with ADHD","volume":"51","year":"2021","unstructured":"Nasser\n              A,\n            \n            \n              Liranso\n              T,\n            \n            \n              Adewole\n              T,\n            \n          \n          .\n\t\t\t\t\tA phase 3 placebo-controlled trial of once daily 400 mg and 600 mg SPN-812 (viloxazine extended release) in adolescents with ADHD.\n\t\t\t\t\tPsychoparmacol Bul.\n\t\t\t\t\t2021;\n\t\t\t\t\t51:\n\t\t\t\t\t43\u2013\n\t\t\t\t\t64."},{"key":"i2331-348X-27-5-409-b12","series-title":"Int J Clin Practice","first-page":"e14330","article-title":"Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended release in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"00","year":"2021","unstructured":"Nasser\n              A,\n            \n            \n              Kosheleff\n              A,\n            \n            \n              Hull\n              J,\n            \n          \n          .\n\t\t\t\t\tEvaluating the likelihood to be helped or harmed after treatment with viloxazine extended release in children and adolescents with attention-deficit\/hyperactivity disorder.\n\t\t\t\t\tInt J Clin Practice.\n\t\t\t\t\t2021;\n\t\t\t\t\t00:\n\t\t\t\t\te14330."},{"issue":"2","key":"i2331-348X-27-5-409-b13","series-title":"J Am Disorders","first-page":"348","article-title":"A phase II double-blind, placebo-controlled, efficacy, and safety study of SPN-812 (extended-release viloxazine) in children with ADHD","volume":"24","year":"2020","unstructured":"Johnson\n              JK,\n            \n            \n              Liranzo\n              T,\n            \n            \n              Saylor\n              K,\n            \n          \n          .\n\t\t\t\t\tA phase II double-blind, placebo-controlled, efficacy, and safety study of SPN-812 (extended-release viloxazine) in children with ADHD.\n\t\t\t\t\tJ Am Disorders.\n\t\t\t\t\t2020;\n\t\t\t\t\t24(\n\t\t\t\t\t2):\n\t\t\t\t\t348\u2013\n\t\t\t\t\t358."},{"issue":"8","key":"i2331-348X-27-5-409-b14","series-title":"Clin Ther","first-page":"1452","article-title":"A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit\/hyperactivity disorder in school-age children","volume":"42","year":"2020","unstructured":"Nasser\n              A,\n            \n            \n              Liranso\n              T,\n            \n            \n              Adewole\n              T,\n            \n          \n          .\n\t\t\t\t\tA phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit\/hyperactivity disorder in school-age children.\n\t\t\t\t\tClin Ther.\n\t\t\t\t\t2020;\n\t\t\t\t\t42(\n\t\t\t\t\t8):\n\t\t\t\t\t1452\u2013\n\t\t\t\t\t1466."},{"issue":"4","key":"i2331-348X-27-5-409-b15","series-title":"Clin Ther","first-page":"684","article-title":"Once daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial","volume":"43","year":"2021","unstructured":"Nasser\n              A,\n            \n            \n              Liranso\n              T,\n            \n            \n              Adewole\n              T,\n            \n          \n          .\n\t\t\t\t\tOnce daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial.\n\t\t\t\t\tClin Ther.\n\t\t\t\t\t2021;\n\t\t\t\t\t43(\n\t\t\t\t\t4):\n\t\t\t\t\t684\u2013\n\t\t\t\t\t700."},{"issue":"4","key":"i2331-348X-27-5-409-b16","series-title":"J Clin Psychopharmacol","first-page":"370","article-title":"A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit\/hyperactivity disorder","volume":"41","year":"2021","unstructured":"Nasser\n              A,\n            \n            \n              Liranso\n              T,\n            \n            \n              Adewole\n              T,\n            \n          \n          .\n\t\t\t\t\tA phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit\/hyperactivity disorder.\n\t\t\t\t\tJ Clin Psychopharmacol.\n\t\t\t\t\t2021:\n\t\t\t\t\t41(\n\t\t\t\t\t4):\n\t\t\t\t\t370\u2013\n\t\t\t\t\t380."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/5\/article-p409.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/27\/5\/409\/3083897\/i2331-348x-27-5-409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/27\/5\/article-p409.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/27\/5\/article-p409.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:35:15Z","timestamp":1747355715000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/5\/article-p409.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":16,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-27.5.409","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2022]]}}}